jak in 5

JAK-IN-5 is a JAK inhibitor.

JAK-IN-5 hydrochloride is a JAK inhibitor [1].

JAK2 inhibitor G5-7 (JAK2 inhibitor G5-7) is an orally active JAK2 inhibitor, selectively inhibits JAK2–mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 has the potential for glioma study

JAK3/BTK-IN-5 is a potent inhibitor of JAK3/BTK. where BTK and JAK3 are two key targets in autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway has a synergistic effect and JAK3/BTK-IN-5 has potential research value for JAK3 kinase and/or BTK-related diseases.

W1131 TFA is a potent STAT3 inhibitor inducing ferroptosis, effectively halting cancer progression in subcutaneous xenograft, organoid, and PDX models of gastric cancer. Besides mitigating chemoresistance to 5-FU in cancer cells, it modulates the cell cycle, DNA damage response, and oxidative phosphorylation, targeting pathways such as IL6-JAK-STAT3 and ferroptosis [1].

5-epi-Arvestonate A, a sesquiterpenoid extracted from Seriphidium transiliense whole plants, enhances melanogenic production by stimulating MITF and tyrosinase family gene transcription. Additionally, it suppresses IFN-γ-chemokine expression via the JAK/STAT signaling pathway in HaCaT cells [1].

W1131, a potent STAT3 inhibitor, effectively triggers ferroptosis and suppresses cancer progression across various models including gastric cancer cell subcutaneous xenograft, organoids, and patient-derived xenograft (PDX). Additionally, W1131 overcomes chemical resistance in cancer cells to 5-FU by regulating cell cycle, DNA damage response, and oxidative phosphorylation pathways, notably the IL6-JAK-STAT3 and ferroptosis pathways [1].

JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC 50 of <5 μM. JAK-IN-14 is more than 8-fold selective for JAK1 than JAK2 and JAK3 [1].

SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.

HAT-SIL-TG-1&AT, a hypoxia-activated prodrug, functions as a Janus tyrosine kinase (JAK) inhibitor demonstrating antitumor effects by inhibiting JAK-STAT signaling within tumor tissues. It also suppresses the proliferation of HEL cells and downregulates phosphorylated STAT3/5 in hypoxic conditions.

JAK-IN-20 is a potent, orally active, broad-based JAK inhibitor, capable of acting on JAK1 (IC50: 7 nM), JAK2 (IC50: 5 nM), and JAK3 (IC50: 14 nM).JAK-IN-20 has excellent pharmacokinetic and anti-inflammatory activity in vivo.

JAK-IN-3 is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively.